ERBB2 and cancer: Similar links between response and FcγR-dependent mechanisms have been observed for additional cancer cell direct-targeting antibodies e.g., herceptin (anti-Her2) and cetuximab (anti-EGFR) in breast cancer (38) and colorectal patients, respectively (37, 39).